daunorubicin has been researched along with u 0126 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Kato, H; Matsusaka, S; Saito, F; Wakabayashi, I | 1 |
| Chen, Y; He, CM; Lin, DJ; Ruan, XX; Wang, LL; Xiao, RZ; Xiong, MJ | 1 |
| Kearns, P; Stankovic, T; Wei, W; Weston, VJ | 1 |
| Amaral, FM; Simeoni, F; Somervaille, TC; Williams, MS | 1 |
5 other study(ies) available for daunorubicin and u 0126
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Inhibitory action of daunorubicin on lipopolysaccharide-stimulated inducible-type nitric oxide synthase induction in alveolar macrophages.
Topics: Animals; Anti-Bacterial Agents; Blood Cell Count; Blotting, Western; Butadienes; Cell Separation; Cell Survival; Daunorubicin; Enzyme Induction; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Lipopolysaccharides; Macrophages, Alveolar; Male; Nitric Oxide; Nitric Oxide Synthase Type II; Nitriles; Rats; Rats, Wistar; Signal Transduction | 2005 |
Inhibition of extracellular signal-regulated kinase activity by sorafenib increases sensitivity to DNR in K562 cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Butadienes; Cell Line, Tumor; Cell Proliferation; Daunorubicin; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; K562 Cells; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Niacinamide; Nitriles; Phenylurea Compounds; Phosphorylation; Signal Transduction; Sorafenib; U937 Cells; Up-Regulation | 2013 |
Synergistic action of dual IGF1/R and MEK inhibition sensitizes childhood acute lymphoblastic leukemia (ALL) cells to cytotoxic agents and involves downregulation of STAT6 and PDAP1.
Topics: Butadienes; Cell Cycle; Chromones; Daunorubicin; Down-Regulation; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Gene Knockdown Techniques; Humans; Intercellular Signaling Peptides and Proteins; MAP Kinase Kinase Kinase 1; Morpholines; Neoplasm Proteins; Nitriles; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Receptor, IGF Type 1; RNA Interference; RNA, Small Interfering; Signal Transduction; STAT6 Transcription Factor; Tumor Cells, Cultured; Tyrphostins; Vincristine | 2018 |
A stress-responsive enhancer induces dynamic drug resistance in acute myeloid leukemia.
Topics: Acetamides; Activating Transcription Factor 4; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Butadienes; Cyclohexylamines; Daunorubicin; Drug Resistance, Neoplasm; Enhancer Elements, Genetic; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; Humans; K562 Cells; Leukemia, Myeloid, Acute; Neoplasm Proteins; Nitriles; Up-Regulation | 2020 |